scholarly journals Endometrial carcinoma metastatic to the scalp

2021 ◽  
Vol 54 (2) ◽  
Author(s):  
Joana Aidos ◽  
Sónia Gonçalves ◽  
Teresa Carvalho ◽  
Nuno Nogueira Martins ◽  
Francisco Nogueira Martins
Keyword(s):  
Endometrial Carcinoma ◽  
Endometrial Adenocarcinoma ◽  
Cutaneous Metastasis ◽  
Scalp Metastasis ◽  
Widespread Dissemination

Endometrial carcinoma is a very rare cause of cutaneous metastasis. The most frequent presentations of cutaneous metastasis are fast developing nodules or tumors, which are evidence of widespread dissemination in such patients. We report a case of scalp metastasis from an endometrial adenocarcinoma with a fatal prognosis.  

Immunocytochemical localization of β1-4 galactosyltransferase in endometrial carcinoma cells

1990 ◽  
Vol 48 (3) ◽  
pp. 944-945
Author(s):  
Ichiro Yamamoto ◽  
Toshiaki Tachibana ◽  
Hiroko Maruyama ◽  
Noriyuki Komatsu ◽  
Hiroyuki Kuramoto ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Cell Lines ◽  
Endometrial Adenocarcinoma ◽  
Protein A ◽  
Rabbit Antiserum ◽  
Carcinoma Cells ◽  
Affinity Column ◽  
Antibody Technique ◽  
Galactosyl Transferase ◽  
C Terminus

We have paid attention to the alteration of glycosyltransferase in carcinoma cells, because it might be related to the malignancy of the cells. In this connection, localization of β1-4 galactosyl transferase (β1-4 Gal T) in human endometrial carcinoma cells was examined immunocytochemically using two kinds of cell lines, each of which showed different degree of differentiation.An antibody was purified from the rabbit antiserum against the synthetic peptide, IFNRLVFRGMSC (W89) of human β1-4 Gal T coupled with KLH (keyhole limpet hemocyanine) by protein A column and peptide-affinity column chromatography. The anti-W89 serum reacts to the C-terminus of human β 1-4 Gal T and to both membrane-bound and soluble forms of the enzyme. Cell line of well differentiated endometrial adenocarcinoma (I) and that of poorly differentiated endometrial adenocarcinoma (50B) were cultivated respectively in MEM medium containing 15% FCS and 2 mM glutamine for 4 d at 37°C under 5% CO2. The cells were fixed in a mixture of 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M Soerensen’s phosphate buffer (pH 7.4) at 4°C for 30 min, washed with PBS, then freezed and thawed. The indirect method of the peroxidase- labeled antibody technique was used for immunocytochemistry of both LM and TEM on the cell lines. The cells were dehydrated in ethanol and embedded in TAAB 812. Ultrathin sections were observed under a TEM, JEM-100S.

PROGESTERONE AND PROGESTATIONAL COMPOUNDS IN THE TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA

1965 ◽  
Vol 49 (3) ◽  
pp. 412-426 ◽  
Author(s):  
Per Bergsjö
Keyword(s):  
Endometrial Carcinoma ◽  
Lung Metastases ◽  
Endometrial Adenocarcinoma ◽  
Cervical Adenocarcinoma ◽  
Tumour Tissue ◽  
Pelvic Tumour ◽  
Histological Alterations

ABSTRACT Various doses of progesterone in oil and of two progestational compounds (17α-hydroxy-19-nor-progesterone caproate and 17α-hydroxyprogesterone p-butoxyphenyl propionate) have been given to 15 patients with recurrent and/or metastatic endometrial adenocarcinoma and to one patient with metastatic cervical adenocarcinoma, for periods of up to 27 weeks. Regression of lung metastases was noted in 4 of 13 patients, softening of pelvic tumour in 2 of 4, and histological alterations of tumour tissue in 4 of 5 patients. In the patient with metastases from a cervical adenocarcinoma, the disease progressed during the treatment. The significance of the observations is discussed.

scholarly journals p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy

2003 ◽  
Vol 121 (4) ◽  
pp. 163-166 ◽  
Author(s):  
Vera Lúcia Leite Bonfitto ◽  
Liliana Aparecida Lucci de Angelo Andrade
Keyword(s):  
Endometrial Carcinoma ◽  
Histological Grade ◽  
Endometrial Adenocarcinoma ◽  
Progesterone Receptors ◽  
Histological Type ◽  
Morphological Data ◽  
Disease Stage ◽  
Biological Behavior ◽  
Endometrioid Carcinoma ◽  
Estrogen And Progesterone Receptors

CONTEXT: Diagnostic staging is an important prognostic factor for endometrial adenocarcinoma. Apart from the histological type and histological grade, some markers seem to be associated with the stage and biological behavior of the disease. Among these are p53, estrogen and progesterone receptors. OBJECTIVE: The objectives of the present study were: to compare histological type and grading of endometrial carcinoma in curettage and hysterectomy samples; to assess expression of p53, estrogen and progesterone receptors in curettage specimens; and to correlate these data with morphology and staging of the disease in hysterectomy specimens. TYPE OF STUDY: Retrospective. SETTING: Department of Pathology, Faculdade de Ciências Médicas, Universidade Estadual de Campinas. SAMPLE: Histological diagnosis from 51 consecutive files. PROCEDURES: Immunohistochemical reactions for p53, estrogen and progesterone receptors via the avidin-biotin-peroxidase method in 51 curettage samples endometrial carcinoma were compared with the morphological data and disease stage in hysterectomy. Marker expression was correlated with histological type and grade and the final stage of the disease. RESULTS: According to the histological type: 44 cases (86%) were of endometrioid and 7 (14%) non-endometrioid carcinoma. p53 expression was observed in 16% of endometrioid and 71% of non-endometrioid cases (p < 0.05). Although estrogen expression was more evident in endometrioid (54%) than non-endometrioid cases (29%), this was not statistically significant. Progesterone receptor expression was significantly higher in endometrioid than non-endometrioid cases (70% vs. 14%, p < 0.05). According to the histological grade: Estrogen and progesterone receptors were expressed more frequently in grade I endometrioid carcinoma, while p53 was mainly reported in tumor grades II and III. According to final disease stage: p53 and estrogen expression in curettage specimens was not related to stage; progesterone receptors, however, were expressed significantly less in advanced disease. CONCLUSION: p53 was observed in the majority of non-endometrioid and in high-grade endometrioid carcinoma, but was not related to stage. Estrogen and progesterone receptors were mainly found in grade I endometrioid carcinoma. The markers studied in curettage were no more valuable for predicting the disease stage than classical histological criteria.

scholarly journals Forgotten Lippes Loop associated with Endometrial Carcinoma

2011 ◽  
Vol 3 (3) ◽  
pp. 147-148
Author(s):  
Smiti Nanda ◽  
Savita Rani Singhal ◽  
Seema Madan
Keyword(s):  
Endometrial Carcinoma ◽  
Vaginal Bleeding ◽  
Intrauterine Device ◽  
Endometrial Adenocarcinoma ◽  
Postmenopausal Bleeding ◽  
Endometrial Sampling

ABSTRACT Patients with a forgotten intrauterine device (IUD) present most often with irregular vaginal bleeding or postmenopausal bleeding. We report a case of nonmedicated IUD (Lippes loop) associated with endometrial adenocarcinoma in a woman who presented with postmenopausal bleeding and a forgotten IUD. Although the occurrence of endometrial adenocarcinoma with IUD is almost unknown, yet given the serious nature of the disease, endometrial sampling is indicated in any patient with postmenopausal bleeding and IUD in situ.

scholarly journals Scalp Metastasis as the First Sign of Small-Cell Lung Cancer: Management and Literature Review

2014 ◽  
Vol 99 (4) ◽  
pp. 325-329 ◽  
Author(s):  
Nikolaos S. Salemis ◽  
Georgios Veloudis ◽  
Kyriakos Spiliopoulos ◽  
Georgios Nakos ◽  
Nikolaos Vrizidis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cutaneous Metastasis ◽  
Small Cell ◽  
Clinical Entity ◽  
Small Cell Lung ◽  
Initial Manifestation ◽  
Cancer Management ◽  
Scalp Metastasis

Abstract Cutaneous metastasis from primary visceral malignancy is a relatively uncommon clinical entity, with a reported incidence ranging from 0.22% to 10% among various series. However, the presence of cutaneous metastasis as the first sign of a clinically silent visceral cancer is exceedingly rare. We describe here a case of an asymptomatic male patient who presented with a solitary scalp metastasis as the initial manifestation of an underlying small-cell lung cancer. Diagnostic evaluation revealed advanced disease. We conclude that the possibility of metastatic skin disease should always be considered in the differential diagnosis in patients with a history of smoking or lung cancer presenting with cutaneous nodules. Physicians should be aware of this rare clinical entity, and appropriate investigation should be arranged for early diagnosis and initiation of the appropriate treatment. The prognosis for most patients remains poor.

Clear Cell Carcinoma of Endometrium

1979 ◽  
Vol 65 (2) ◽  
pp. 201-205 ◽  
Author(s):  
Silvestro G. Carinelli ◽  
Francomaria Senzani
Keyword(s):  
Cell Carcinoma ◽  
Endometrial Carcinoma ◽  
Sex Hormones ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Endometrial Adenocarcinoma

Three cases of clear cell carcinoma of the endometrium are here reported. Clear cell carcinoma is a rare and aggressive type of endometrial adenocarcinoma. Patients are older and are in the menopause much longer than are patients with typical endometrial carcinoma. This fact may reflect the presence of counterbalanced sex hormones in the process of carcinogenesis.

Detection of chromosomal anomalies in uterine endometrial carcinoma using fluorescence in situ hybridization (UteroFISH)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5533-5533
Author(s):  
J. Qian ◽  
D. Weber ◽  
R. Cochran ◽  
D. Hossain ◽  
D. G. Bostwick
Keyword(s):  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Endometrial Carcinoma ◽  
Endometrial Adenocarcinoma ◽  
Atypical Hyperplasia ◽  
Chromosome 1 ◽  
Chromosomal Anomalies ◽  
Tissue Samples ◽  
Gynecological Malignancy

5533 Background: Endometrial cancer is the most common pelvic gynecological malignancy. The diagnosis of well-differentiated endometrial adenocarcinoma, atypical hyperplasia, and marked hyperplasia is often challenging. We sought to investigate the utility of chromosomal anomalies for the detection of uterine endometrial carcinoma using multitarget fluorescence in situ hybridization (FISH). Methods: Samples were collected by endometrial brush and processed by liquid-based thin-layer cytological preparation protocol. For study, we collected cytology slides from consecutive cases to include 50 benign, 50 hyperplasia without atypia, 50 atypical hyperplasia, and 50 endometrial cancers. Each was hybridized using fluorescence labeled DNA probes to chromosomes 1, 8, and 10 (UteroFISH). The FISH signals were enumerated in 100 cells per case, and the chromosomal anomalies were correlated with pathologic findings, including histologic diagnoses on endometrial tissue samples. Results: Numeric chromosomal anomalies were found in 0% (0/50) of benign, 20% (10/50) of hyperplasia, 76% of atypical hyperplasia (38/50), and 86% (43/50) of carcinoma specimens. The mean percentage of cells with chromosomal changes was 54% in cancer specimens, significantly higher than that in hyperplasia without atypia (13%, p< 0.0001) and atypical hyperplasia (34%, p< 0.0001). The most frequent chromosomal anomaly was gain of chromosome 1. FISH anomalies had an overall sensitivity of 81% and specificity of 90% for the detection of atypical hyperplasia and/or endometrial carcinoma. There was no association with grade of endometrial carcinoma. Conclusions: Multi-target UteroFISH appeared to be useful for the differential diagnosis of reactive hyperplasia, atypical hyperplasia, and endometrial adenocarcinoma, with a high level of sensitivity and specificity. Endometrial hyperplasia with FISH-detected chromosomal anomalies may require close clinical follow-up. No significant financial relationships to disclose.

P–339 Fertility treatment and live birth are still possible following the unexpected diagnosis of endometrial carcinoma/complex hyperplasia - provided that there is careful multidisciplinary team involvement

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
D Roche ◽  
F Martyn ◽  
M Wingfield
Keyword(s):  
Surgical Treatment ◽  
Endometrial Carcinoma ◽  
Embryo Transfer ◽  
Live Birth ◽  
Conservative Management ◽  
Endometrial Adenocarcinoma ◽  
Case Series ◽  
Endometrial Biopsy ◽  
Fertility Treatment ◽  
Fertility Clinic

Abstract Study question Is it safe for young women to delay hysterectomy for endometrial carcinoma or complex hyperplasia, have fertility treatment and carry a pregnancy to term? Summary answer Fertility treatment and livebirth are possible after a diagnosis of endometrial carcinoma or complex hyperplasia but close co-operation between fertility and gynae-oncology services is key. What is known already While predominantly a disease of postmenopausal women, 7% of cases of endometrial adenocarcinoma or complex hyperplasia occur in women under 40 years. The standard surgical treatment is hysterectomy, which is curative in the majority of cases. In younger women wishing to preserve fertility, conservative treatment may be considered. The fertility outcomes in this population are not well reported, possibly because fertility preservation is not always discussed or considered when faced with the devastating diagnosis of cancer or pre-cancer in the younger woman or because of concerns regarding the impact of pregnancy or ovarian stimulation on a predominantly oestrogen sensitive tumour. Study design, size, duration This case series retrospectively evaluated the outcomes of 6 women with endometrial adenocarcinoma or complex hyperplasia who attended Merrion Fertility Clinic, Dublin from 2013 to 2020 and who were managed conservatively. These women initially presented with a history of infertility for which they underwent routine ultrasonography, which then led to hysteroscopy and endometrial biopsy. The histopathology of all 6 women showed an incidental finding of endometrial adenocarcinoma or complex hyperplasia. Participants/materials, setting, methods Patient files and a fertility clinic online database were reviewed to identify those with a diagnosis of endometrial carcinoma or complex hyperplasia. Their treatment course and reproductive outcomes were followed up, as was there eventual definitive surgical treatment. Main results and the role of chance Six women attending our service over a 7 year period were found to have endometrial adenocarcinoma or hyperplasia. They ranged in age from 34 to 46(mean 39). All were nulliparous. Four of the women had adenocarcinoma and 2 had complex hyperplasia. One woman, aged 41, with grade II endometrial adencocarcinoma was deemed unsuitable for conservative management by the gynaecological oncology team. She underwent urgent total abdominal hysterectomy and is well. The remaining 5 women proceeded with conservative management with oral or local progesterone therapy for 6 to 12 months. This resulted in an inactive endometrium on follow-up endometrial biopsy. Once disease regression was achieved, assisted reproduction in the form of in-vitro fertilization (IVF) was advised to ensure minimal time to pregnancy. Two of the women conceived using own egg IVF and two with donor eggs. All were successful in achieving at least one live birth. One had twins and one had 2 singletons, from a fresh and a frozen embryo transfer. The 6th woman has embryos frozen but has not yet had embryo transfer. Two of the 6 women ultimately had a hysterectomy, while 4 continue to be followed up with 6 monthly endometrial biopsies and progesterone therapy. Limitations, reasons for caution This study is limited by the small sample size. However, this paper reports on a niche subset of the population and finding larger sample sizes would be difficult to obtain. Wider implications of the findings: This case series illustrates the favourable outcome of pregnancy with IVF after either systemic or local progesterone therapy in early stage endometrial adenocarcinoma or complex hyperplasia. Early involvement of a fertility specialist may prove highly valuable in cases of fertility sparing treatment to increase each patient’s potential for pregnancy. Trial registration number Not applicable

Adult Granulosa Cell Tumor Associated with Endometrial Carcinoma

2016 ◽  
Vol 8 (3) ◽  
pp. 246-248
Author(s):  
Archana Baser ◽  
Alia K Zaidi ◽  
Nikita Sanghvi
Keyword(s):  
Endometrial Carcinoma ◽  
Granulosa Cell ◽  
Histopathological Examination ◽  
Endometrial Adenocarcinoma ◽  
Granulosa Cell Tumor ◽  
Cell Tumor ◽  
Ovarian Tumors ◽  
Granulosa Cell Tumors ◽  
Good Imaging ◽  
Endometrial Carcinomas

ABSTRACT Adult granulosa cell tumors account for approximately 1 and 2% of all ovarian tumors and 95% of all granulosa cell tumors. They occur more often in postmenopausal than in premenopausal women, with a peak incidence between 50 and 55 years of age. They are the most common estrogenic ovarian tumors diagnosed clinically. The typical endometrial reaction associated with functional tumors in this category is simple hyperplasia that usually exhibits some degree of precancerous atypicality. The incidence of associated endometrial carcinomas is under 5%, and most of these endometrial cancers are well-differentiated endometrioid adenocarcinomas that carry a good prognosis when detected early. We report the case of a 85-year-old woman with endometrial adenocarcinoma and adult granulose cell tumor of the ovary who presented with postmenopausal bleeding and adnexal mass. She underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy, infracolic omentectomy, and pelvic lymphadenectomy, and the specimen was submitted for histopathological examination. She had a good postoperative recovery and was discharged 5 days after treatment. The association between adult granulosa cell tumors of the ovary and endometrial carcinomas is rare. A high index of suspicion and good imaging and histopathologic analyses are important in making this diagnosis. How to cite this article Baser A, Zaidi AK, Sanghvi N. Adult Granulosa Cell Tumor Associated with Endometrial Carcinoma. J South Asian Feder Obst Gynae 2016;8(3):246-248.

Sign in / Sign up

Export Citation Format

Share Document